Immunotherapy and Chemoradiation for Advanced Esophageal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immunotherapy (adebrelimab) plus standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery. The goal is to see if adding the immunotherapy before and during chemoradiation helps control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have esophageal squamous cell cancer that has not spread too far, and surgery is not planned or possible.
- You have not had any previous cancer treatment (like chemo, radiation, or surgery) for this cancer.
- You are in good enough health to do daily activities (ECOG score 0 or 1).
- You do not have an active autoimmune disease, an active infection, or a history of certain other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests a drug called adebrelimab (an immunotherapy) combined with chemotherapy and radiation for people with advanced esophageal cancer that cannot be removed by surgery or has come back after surgery. It aims to see if the combination is safe and effective.
This trial tests a new approach for people with a certain type of esophageal cancer. Instead of surgery right away, you would receive chemotherapy, radiation, and an immunotherapy drug called adebrelimab. After that, doctors will closely watch your cancer to see if it's gone. The goal is to avoid surgery if the treatment works well.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial tests an immunotherapy drug (adebrelimab) combined with chemotherapy before standard chemoradiation for people with locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.